NCT00684463View on ClinicalTrials.gov

Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED)

PHASE4CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

April 11, 2007

Primary Completion Date

February 22, 2008

Study Completion Date

February 22, 2008

Conditions
NeoplasmsNauseaVomiting
Interventions
DRUG

Palonosetron

0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00684463 - Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED) | Biotech Hunter | Biotech Hunter